MARKET PULSE Snap Inc. (SNAP) on Monday introduced a new AI feature on its platform, a chatbot powered by OpenAI for paying users. The chatbot, called My AI, is available to users who subscribe to Snapchat+, the company’s $3. Read More...
Benzinga
Why Reata Pharmaceuticals Shares Are Falling Monday?
According to various reports, the FDA’s neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. Dunn presided over the controversial approval of Biogen Inc’s (NASDAQ: BIIB) Alzheimer’s disease treatment, Aduhelm (aducanumab). Dunn, 53, is retiring from the agency to “explore other opportunities,” according to an internal FDA email. Dunn notified agency officials Friday, according to a person with knowledge of the situation. Reata Pharmaceuticals Inc
